Evidence map›Paper›PMID 36926347›Full record

ReviewFrontiers in immunology2023

Recapitulating essential pathophysiological characteristics in lung-on-a-chip for disease studies.

Yanning Zhang, Xuejiao Wang, Yaoqing Yang, Jing Yan, Yanlu Xiong, Wenchen Wang, Jie Lei, Tao Jiang

Full text readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. The evolution ofEuropean respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  10. Review
  11. Endothelin-1 in Health and Disease.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yanning ZhangDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, China.
Xuejiao WangDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, China.
Yaoqing YangDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, China.
Jing YanDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, China.
Yanlu XiongDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, China.
Wenchen WangDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, China.
Jie LeiDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, China.
Tao JiangDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung diseases have become a significant challenge to public healthcare worldwide, which stresses the necessity of developing effective biological models for pathophysiological and pharmacological studies of the human respiratory system. In recent years, lung-on-a-chip has been extensively developed as a potentially revolutionary respiratory model paradigm with high efficiency and improved accuracy, bridging the gap between cell culture and preclinical trials. The advantages of lung-on-a-chip technology derive from its capabilities in establishing 3D multicellular architectures and dynamic microphysiological environments. A critical issue in its development is utilizing such capabilities to recapitulate the essential components of the human respiratory system for effectively restoring physiological functions and illustrating disease progress. Here we present a review of lung-on-a-chip technology, highlighting various strategies for capturing lung physiological and pathological characteristics. The key pathophysiological characteristics of the lungs are examined, including the airways, alveoli, and alveolar septum. Accordingly, the strategies in lung-on-a-chip research to capture the essential components and functions of lungs are analyzed. Recent studies of pneumonia, lung cancer, asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis based on lung-on-a-chip are surveyed. Finally, cross-disciplinary approaches are proposed to foster the future development of lung-on-a-chip technology.

Indexed as

AsthmaLung DiseasesPulmonary Disease, Chronic ObstructiveHumansLab-On-A-Chip DevicesLungdiagnosislung diseaseslung-on-a-chipmicroengineering technologypathophysiology

Identifiers

PMID36926347
PMCPMC10012278

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read14
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.